Three companies collaborated to evaluate the efficacy of Stivarga and Opdivo (nivolumab) in the trea

News

TEL：+86-21-33585366（DDT）
     34666753、33588661
FAX：+86-21-34979012
Q Q：  2762556331（Domestic）
      3501899018（Export）
E-mail：info@shyrchem.com
Domestic：sales@shyrchem.com
Export：sales02@shyrchem.com

Your current location：Home > News > Industry News

Three companies collaborated to evaluate the efficacy of Stivarga and Opdivo (nivolumab) in the trea

Time：2019-07-24 14:36:41 Source： Author：

Recently, Bayer, Bristol-Myers Squibb (BMS) and Ono Pharmaceuticals (http://www.chemdrug.com/) announced that three companies (http://www.chemdrug.com/company/) had signed clinical cooperation agreements to evaluate Stivar (regorafenib), a kinase inhibitor in Bayer. Efficacy of combination with BMS/Ono Pharmaceutical Co., Ltd. Opdivo (nivolumab), an anti-PD-1 monoclonal antibody.

The combination therapy is used to treat microsatellite stable metastatic colorectal cancer (MSS mCRC).

On Stivarga

Stivarga is a multikinase inhibitor that inhibits a variety of kinases that promote tumor growth, including kinases that mediate vascular endothelial growth factor (VEGF) signaling pathways.

Stivarga, as a single therapy, showed overall survival benefits compared with placebo in key phase 3 CORRECT clinical studies and showed microsatellite-like features in a retrospective analysis of the study (http://www.chemdrug.com/sell/76/).

State-independent activity.

Previously, Stivarga was approved for the treatment of patients with hepatocellular carcinoma, metastatic CRC, and locally advanced, unresectable or metastatic gastrointestinal stromal tumors (GIST).

On Opdivo

Opdivo is a PD-1 inhibitor designed to help restore the anti-tumor immune response. Opdivo has become an important treatment option for many cancers by using the body's own immune system to fight cancer.

The early data used by Stivarga and Opdivo is exciting. In a phase 1b clinical trial called REGONIVO (http://www.chemdrug.com/sell/24/), the combination of Stivarga and Opdivo has shown good initial efficacy.

Last Next